McKesson — May 7, 2026 release

• McKesson remains committed to a disciplined capital allocation framework, prioritizing investments in high-margin growth areas while returning excess capital to shareholders through our robust share repurchase program. ◦ The Board of Directors approved an additional $5.0 billion share repurchase authorization of the company's common shares, bringing total authorized repurchases to $7.7 billion as of April 2026. ◦ During the fourth quarter, McKesson entered into a $2.25 billion accelerated share repurchase program. In the quarter, McKesson completed $2.7 billion share repurchases, including $2.25 billion under the accelerated share repurchase program. • In April 2026, The US Oncology Network expanded its footprint with the addition of Cancer Care Northwest, strengthening its position in community oncology practices. • Effective May 1, 2026, PRISM Vision Group grew its network by welcoming the Retina Macula Institute located in Southern California further aligning with ophthalmology practices nationwide. • McKesson signed a definitive agreement under which Apollo Global will acquire approximately 13% minority ownership interest in the Medical-Surgical Solution segment, subject to regulatory approvals and customary closing conditions. • In April 2026, McKesson completed initial financing transactions in support of the planned separation of Medical-Surgical Solutions segment, including a secured $1.0 billion term loan and $1.0 billion revolving credit facility. • On January 30, 2026, McKesson closed the transaction to sell its retail and distribution businesses in Norway, r